Treatment of epidermolysis bullosa simplex, Weber-Cockayne type, with botulinum toxin type A

Archives of Dermatology

Volumn 145, Issue 1, 2009, Pages 13-15

  Abitbol, Roxanne J ^a,b   Zhou, Linda Hua ^a  

^a ROGER WILLIAMS MEDICAL CENTER   (United States)

^b South Nassau Dermatology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM CHLORIDE; BOTULINUM TOXIN A; SODIUM CHLORIDE; TETRACYCLINE;

ABSENCE OF SIDE EFFECTS; ADULT; ANAMNESIS; ARTICLE; BLISTER; BULLOUS SKIN DISEASE; CASE REPORT; CLINICAL FEATURE; DEVICE; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EPIDERMOLYSIS BULLOSA SIMPLEX; EROSION; FEMALE; FOLLOW UP; HUMAN; PHYSICAL EXAMINATION; PRIORITY JOURNAL; TREATMENT DURATION; WOUND ASSESSMENT;

ADULT; BOTULINUM TOXIN TYPE A; EPIDERMOLYSIS BULLOSA SIMPLEX; FEMALE; FOOT DISEASES; HUMANS; HYPERHIDROSIS; INJECTIONS;

EID: 58849103424     PISSN: 0003987X     EISSN: 15383652     Source Type: Journal    
DOI: 10.1001/archdermatol.2008.546     Document Type: Article

References (16)

1. Jennings JL. Aluminum chloride hexahydrate treatment of localized epidermolysis bullosa. Arch Dermatol. 1984;120(10):1382.
2. Tkach JR. Treatment of recurrent bullous eruption of the hands and feet (Weber-Cockayne disease) with topical aluminum chloride. J Am Acad Dermatol. 1982;6(6):1095-1096.
3. Younger IR, Priestley GC, Tidman MJ. Aluminum chloride hexahydrate and blistering in epidermolysis bullosa simplex. J Am Acad Dermatol. 1990;23(5, pt1):930-931.
4. Moy JA, Caldwell-Brown D, Lin AN, Pappa KA, Carter DM. Mupirocin-resistant Staphylococcus aureus after long-term treatment of patients with epidermolysis bullosa. J Am Acad Dermatol. 1990;22(5, pt 1):893-895.
5. Fine JD, Johnson L. Evaluation of the efficacy of topical bufexamac in epidermolysis bullosa simplex. Arch Dermatol. 1988;124(11):1669-1672.
6. Retief CR, Malkinson FD, Pearson RW. Two familial cases of epidermolysis bullosa simplex successfully treated with tetracycline. Arch Dermatol. 1999;135(8):997-998.
7. Fine JD, Eady RA. Tetracycline and epidermolysis bullosa simplex: a new indication for one of the oldest and most widely used drugs in dermatology? Arch Dermatol. 1999;135(8):981-982.
8. Weiner M, Stein A, Cash S. Tetracycline and epidermolysis bullosa simplex: a double-blind, placebo-controlled, crossover randomized clinical trial. Br J Dermatol. 2004;150(3):613-614.
9. Neufeld-Kaiser W, Sybert VP. Is cyproheptadine effective in the treatment of subjects with epidermolysis bullosa simplex-Dowling-Meara? Arch Dermatol. 1997;133(2):251-252.
10. Tadini G, Ermacora E, Cambiaghi S, Brusasco A, Cavalli R. Positive response to 5HT-2 antagonists in a family affected by epidermolysis bullosa Dowling-Meara type. Dermatology. 1993;186(1):80.
11. Schnider P, Binder M, Auff E. Double-blind trial of botulinum A toxin for the treatment of focal hyperhidrosis of the palms. Br J Dermatol. 1997;136(4):548-552.
12. Vadoud-Seyedi J. Treatment of plantar hyperhidrosis with botulinum toxin type A. Int J Dermatol. 2004;43(12):969-971.
13. Fujita M, Mann T, Mann O, et al. Surgical pearl: use of nerve blocks for botulinum toxin treatment of palmer-plantar hyperhidrosis. J Am Acad Dermatol. 2001;45(4):587-589.
14. Goldsmith LA. Mutations in epidermolysis bullosa simplex. J Invest Dermatol. 1995;105(4):529-531.
15. Okulicz JF, Kihiczak NI, Janniger CK. Epidermolysis bullosa simplex. Cutis. 2002;70(1):19-21.
16. Naylor PFD. Experimental friction blisters. Br J Dermatol. 1955;67(10):327-342.